{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:58Z","timestamp":1789504078719,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Medical Health Science and Technology Project of Shandong Provincial Health Commission","award":["202104120294"],"award-info":[{"award-number":["202104120294"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aesth Plast Surg"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00266-022-03018-y","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T17:03:10Z","timestamp":1663002190000},"page":"365-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-6499","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"issue":"12","key":"3018_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/jdv.12408","volume":"28","author":"BJ Kim","year":"2014","unstructured":"Kim BJ, Kwon HH, Park SY et al (2014) Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines. J Eur Acad Dermatol Venereol 28(12):1761\u20131767","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3018_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/DSS.0000000000002143","volume":"46","author":"M Kawashima","year":"2020","unstructured":"Kawashima M, Harii K, Horiuchi Y et al (2020) Safety, efficacy, and patient satisfaction with onabotulinumtoxin A for the treatment of upper facial lines in Japanese subjects. Dermatol Surg 46(4):483\u2013490","journal-title":"Dermatol Surg"},{"issue":"6","key":"3018_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dsu.12160","volume":"39","author":"C William Hanke","year":"2013","unstructured":"William Hanke C, Narins RS, Brandt F et al (2013) A randomized, placebo-controlled, double-blind phase iii trial investigating the efficacy and safety of incobotulinumtoxin A in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg 39(6):891\u2013899","journal-title":"Dermatol Surg"},{"issue":"3","key":"3018_CR4","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1097\/DSS.0000000000002789","volume":"47","author":"KH Yoo","year":"2021","unstructured":"Yoo KH, Lee YW, Lee JS et al (2021) Efficacy and safety of a new botulinum toxin (HU-014) versus existing onabotulinumtoxin A in subjects with moderate to severe glabellar lines. Dermatol Surg 47(3):e91\u2013e96","journal-title":"Dermatol Surg"},{"issue":"6","key":"3018_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","volume":"42","author":"E Gubanova","year":"2018","unstructured":"Gubanova E, Haddad TM, Bergerova Y et al (2018) Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport((R))\/Azzalure((R))): primary results of the APPEAL noninterventional study. Aesthetic Plast Surg 42(6):1672\u20131680","journal-title":"Aesthetic Plast Surg"},{"issue":"6","key":"3018_CR6","doi-asserted-by":"publisher","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","volume":"142","author":"SG Yoelin","year":"2018","unstructured":"Yoelin SG, Dhawan SS, Vitarella D et al (2018) Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast Reconstr Surg 142(6):847e\u2013855e","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"3018_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/asj\/sjz003","volume":"40","author":"B Ascher","year":"2020","unstructured":"Ascher B, Rzany B, Kestemont P et al (2020) Liquid formulation of AbobotulinumtoxinA: A 6-month, phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surg J 40(1):93\u2013104","journal-title":"Aesthetic Surg J"},{"issue":"6","key":"3018_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/asj\/sjaa220","volume":"41","author":"MA Polacco","year":"2021","unstructured":"Polacco MA, Singleton AE, Barnes CH et al (2021) A double-blind, randomized clinical trial to determine effects of increasing doses and dose-response relationship of incobotulinumtoxin A in the treatment of glabellar rhytids. Aesthetic Surg J 41(6):500\u2013511","journal-title":"Aesthetic Surg J"},{"issue":"5","key":"3018_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/DSS.0000000000001779","volume":"45","author":"P Ogilvie","year":"2019","unstructured":"Ogilvie P, Rivkin AZ, Dayan S et al (2019) Onabotulinumtoxin A for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from a phase 3 double-blind study. Dermatol Surg 45(5):689\u2013699","journal-title":"Dermatol Surg"},{"issue":"11","key":"3018_CR10","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/DSS.0000000000000531","volume":"41","author":"MA Kane","year":"2015","unstructured":"Kane MA, Gold MH, Coleman WR et al (2015) A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxin A and onabotulinumtoxin A for glabellar frown lines. Dermatol Surg 41(11):1310\u20131319","journal-title":"Dermatol Surg"},{"issue":"6","key":"3018_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3109\/14764172.2012.738913","volume":"14","author":"M Moers-Carpi","year":"2012","unstructured":"Moers-Carpi M, Dirschka T, Feller-Heppt G et al (2012) A randomised, double-blind comparison of 20 units of onabotulinumtoxin A with 30 units of incobotulinumtoxin A for glabellar lines. J Cosmet Laser Ther 14(6):296\u2013303","journal-title":"J Cosmet Laser Ther"},{"issue":"4","key":"3018_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/DSS.0000000000002846","volume":"47","author":"J Schlessinger","year":"2021","unstructured":"Schlessinger J, Cohen JL, Shamban A et al (2021) A multicenter study to evaluate subject satisfaction with two treatments of abobotulinumtoxin A a year in the glabellar lines. Dermatol Surg 47(4):504\u2013509","journal-title":"Dermatol Surg"},{"issue":"10","key":"3018_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1097\/DSS.0000000000001926","volume":"45","author":"J Kaufman","year":"2019","unstructured":"Kaufman J, Cohen JL, Peredo MI et al (2019) Clinical assessment of 2 licensed abobotulinumtoxin A injection volumes for the treatment of glabellar lines. Dermatol Surg 45(10):1274\u20131284","journal-title":"Dermatol Surg"},{"issue":"9","key":"3018_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.36849\/JDD.6130","volume":"20","author":"J Schlessinger","year":"2021","unstructured":"Schlessinger J, Friedmann DP, Mayoral F et al (2021) Abobotulinumtoxin A treatment of glabellar lines using a new reconstitution and injection volume: randomized, Placebo-controlled data. J Drugs Dermatol 20(9):988\u2013995","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"3018_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/asj\/sjab329","volume":"42","author":"P Kestemont","year":"2022","unstructured":"Kestemont P, Hilton S, Andriopoulos B et al (2022) Long-term efficacy and safety of liquid abobotulinumtoxina formulation for moderate-to-severe glabellar lines: a phase III, double-blind, randomized, placebo-controlled and open-label study. Aesthetic Surg J 42(3):301\u2013313","journal-title":"Aesthetic Surg J"},{"issue":"7","key":"3018_CR16","first-page":"776","volume":"40","author":"D Jones","year":"2014","unstructured":"Jones D, Carruthers J, Narins RS et al (2014) Efficacy of incobotulinumtoxin A for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials. Dermatol Surg 40(7):776\u2013785","journal-title":"Dermatol Surg"},{"issue":"4","key":"3018_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/dsu.12100","volume":"39","author":"A Carruthers","year":"2013","unstructured":"Carruthers A, Carruthers J, Coleman WR et al (2013) Multicenter, randomized, phase III study of a single dose of incobotulinumtoxin A, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg 39(4):551\u2013558","journal-title":"Dermatol Surg"},{"issue":"Suppl 4","key":"3018_CR18","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1111\/j.1524-4725.2010.01706.x","volume":"36","author":"G Sattler","year":"2010","unstructured":"Sattler G, Callander MJ, Grablowitz D et al (2010) Noninferiority of incobotulinumtoxin A, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 36(Suppl 4):2146\u20132154","journal-title":"Dermatol Surg"},{"issue":"11","key":"3018_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","volume":"45","author":"KR Beer","year":"2019","unstructured":"Beer KR, Shamban AT, Avelar RL et al (2019) Efficacy and safety of prabotulinumtoxin A for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg 45(11):1381\u20131393","journal-title":"Dermatol Surg"},{"issue":"4","key":"3018_CR20","first-page":"413","volume":"40","author":"BJ Rzany","year":"2020","unstructured":"Rzany BJ, Ascher B, Avelar RL et al (2020) A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxin A and onabotulinumtoxin A for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J 40(4):413\u2013429","journal-title":"Aesthet Surg J"},{"issue":"2","key":"3018_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ijd.12627","volume":"54","author":"CH Won","year":"2015","unstructured":"Won CH, Kim HK, Kim BJ et al (2015) Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxin A in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol 54(2):227\u2013234","journal-title":"Int J Dermatol"},{"issue":"Suppl 3","key":"3018_CR22","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1097\/DSS.0000000000001364","volume":"43","author":"V Bertucci","year":"2017","unstructured":"Bertucci V, Humphrey S, Carruthers J et al (2017) Comparing injectable daxibotulinumtoxin A and onabotulinumtoxin A in moderate and severe glabellar lines: additional analyses from a phase 2, randomized, dose-ranging, double-blind, multicenter study. Dermatol Surg 43(Suppl 3):S262\u2013S273","journal-title":"Dermatol Surg"},{"issue":"3","key":"3018_CR23","doi-asserted-by":"publisher","first-page":"310e","DOI":"10.1097\/PRS.0000000000001544","volume":"136","author":"Y Guo","year":"2015","unstructured":"Guo Y, Lu Y, Liu T et al (2015) Efficacy and safety of botulinum toxin type A in the treatment of glabellar lines: a meta-analysis of randomized, Placebo-controlled, double-blind trials. Plast Reconstr Surg 136(3):310e\u2013318e","journal-title":"Plast Reconstr Surg"},{"issue":"11","key":"3018_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"3018_CR25","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2020","unstructured":"Higgins JPT (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Springer, Berlin","edition":"2"},{"key":"3018_CR26","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q et al (2019) Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res 2019:2546161","journal-title":"J Immunol Res"},{"issue":"9","key":"3018_CR27","doi-asserted-by":"publisher","first-page":"980","DOI":"10.36849\/JDD.6263","volume":"20","author":"J Joseph","year":"2021","unstructured":"Joseph J, Moradi A, Lorenc ZP et al (2021) Abobotulinumtoxin A for the treatment of moderate-to-severe glabellar lines: a randomized, dose-escalating, double-blind study. J Drugs Dermatol 20(9):980\u2013987","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"3018_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","volume":"46","author":"GD Monheit","year":"2020","unstructured":"Monheit GD, Baumann L, Maas C et al (2020) Efficacy, safety, and subject satisfaction after abobotulinumtoxin A treatment for moderate to severe glabellar lines. Dermatol Surg 46(1):61\u201369","journal-title":"Dermatol Surg"},{"issue":"12","key":"3018_CR29","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","volume":"35","author":"F Brandt","year":"2009","unstructured":"Brandt F, Swanson N, Baumann L et al (2009) Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 35(12):1893\u20131901","journal-title":"Dermatol Surg"},{"issue":"2","key":"3018_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/asj\/sjw272","volume":"38","author":"B Ascher","year":"2018","unstructured":"Ascher B, Kestemont P, Boineau D et al (2018) Liquid formulation of Abobotulinumtoxin A exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surg J 38(2):183\u2013191","journal-title":"Aesthetic Surg J"},{"issue":"6","key":"3018_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dsu.12160","volume":"39","author":"CW Hanke","year":"2013","unstructured":"Hanke CW, Narins RS, Brandt F et al (2013) A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxin A in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg 39(6):891\u2013899","journal-title":"Dermatol Surg"},{"issue":"4","key":"3018_CR32","first-page":"413","volume":"40","author":"BJ Rzany","year":"2020","unstructured":"Rzany BJ, Ascher B, Avelar RL et al (2020) A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxin A and onabotulinumtoxin A for the treatment of moderate to severe glabellar lines in adult patients. Aesthetic Surg J 40(4):413\u2013429","journal-title":"Aesthetic Surg J"},{"issue":"11","key":"3018_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","volume":"43","author":"JD Carruthers","year":"2017","unstructured":"Carruthers JD, Fagien S, Joseph JH et al (2017) Injectable daxibotulinumtoxina for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxina and placebo. Dermatol Surg 43(11):1321\u20131331","journal-title":"Dermatol Surg"},{"issue":"1","key":"3018_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","volume":"145","author":"JD Carruthers","year":"2020","unstructured":"Carruthers JD, Fagien S, Joseph JH et al (2020) Daxibotulinumtoxin A for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg 145(1):45\u201358","journal-title":"Plast Reconstr Surg"},{"issue":"10","key":"3018_CR35","first-page":"1052","volume":"20","author":"M Kerscher","year":"2021","unstructured":"Kerscher M, Fabi S, Fischer T et al (2021) Incobotulinumtoxin A demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines. J Drugs Dermatol JDD 20(10):1052\u20131060","journal-title":"J Drugs Dermatol JDD"},{"issue":"1","key":"3018_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/DSS.0000000000002531","volume":"47","author":"SG Fabi","year":"2021","unstructured":"Fabi SG, Cohen JL, Green LJ et al (2021) Daxibotulinumtoxin A for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg 47(1):48\u201354","journal-title":"Dermatol Surg"},{"issue":"12","key":"3018_CR37","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/DSS.0000000000003211","volume":"47","author":"R Glogau","year":"2021","unstructured":"Glogau R, Kontis TC, Liu Y et al (2021) Progressive improvement in static glabellar lines after repeated treatment with daxibotulinumtoxina for injection. Dermatol Surg 47(12):1579\u20131584","journal-title":"Dermatol Surg"},{"issue":"4","key":"3018_CR38","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","volume":"82","author":"V Bertucci","year":"2020","unstructured":"Bertucci V, Solish N, Kaufman-Janette J et al (2020) DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol 82(4):838\u2013845","journal-title":"J Am Acad Dermatol"}],"container-title":["Aesthetic Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00266-022-03018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00266-022-03018-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00266-022-03018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T21:24:51Z","timestamp":1701033891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00266-022-03018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3018"],"URL":"https:\/\/doi.org\/10.1007\/s00266-022-03018-y","relation":{},"ISSN":["0364-216X","1432-5241"],"issn-type":[{"value":"0364-216X","type":"print"},{"value":"1432-5241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflict of interest was reported by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"For this type of study, informed consent is not required.For this type of study, informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}